BFC Planning’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$713 Hold
22
– – ﹤0.01% 3235
2026
Q2
$819 Hold
22
– – ﹤0.01% 3184
2026
Q1
$698 Hold
22
– – ﹤0.01% 2800
2025
Q4
$598 Hold
22
– – ﹤0.01% 2891
2025
Q3
$569 Buy
+22
New +$510 ﹤0.01% 2729

Other funds holding CLDX

BFC Planning's CLDX Position: Q3 2026 in Review

BFC Planning held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 22 shares worth $713. The position accounts for ﹤0.01% of the portfolio, ranked #3235.

BFC Planning first reported a position in CLDX in Q3 2025 and has held it in 5 quarters since. The position peaked at $819 in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • BFC Planning held 22 shares of Celldex Therapeutics worth $713 as of Q3 2026.
  • BFC Planning left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3235 holding.
  • BFC Planning first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • BFC Planning's Celldex Therapeutics position peaked at $819 in Q2 2026.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.